Argos Therapeutics

Argos Therapeutics

A company developing immunotherapy treatments for cancers, infectious and autoimmune diseases

All edits

Edits on 30 June, 2020
Henry Ogolla"Approved suggestion #805186"
Henry Ogolla edited on 30 June, 2020 2:36 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 24 November, 2019
Golden AI
Golden AI edited on 24 November, 2019 12:41 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 7 November, 2019
Golden AI
Golden AI edited on 7 November, 2019 5:14 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 June, 2019
Golden AI
Golden AI edited on 12 June, 2019 10:42 pm
Edits made to:
Infobox (+1 properties)
Infobox
Golden AI
Golden AI edited on 12 June, 2019 10:12 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 25 April, 2019
Golden AI
Golden AI edited on 25 April, 2019 12:52 am
Edits made to:
Infobox (+2 properties)
Infobox
Edits on 29 March, 2019
Dawson Sewell
Dawson Sewell edited on 29 March, 2019 10:44 pm
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Edits on 29 March, 2019
Dawson Sewell
Dawson Sewell edited on 29 March, 2019 7:22 pm
Edits made to:
Infobox (+5 properties)
Article (+106/-15 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)
Article

Argos Therapeutics is a publicly funded immuno-oncology company based in Durham, North Carolina that was founded in 1997 by Ralph M. Steinman. It is focused on the development and commercialization of individualized immunotherapiesimmunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. The technology creates individualized immunotherapies that harness and reprogram dendritic cells to target antigens specific to each person's disease.

Products

AGS-003

...

AGS-004

...

Bankruptcy announcement

In December 2018, Argos Therapeutics filed for bankruptcy protection with the U.S. Bankruptcy Court in Delaware. NASDAQ had also delisted the company's shares earlier in April 2018.

Infobox
Categories
Related Topics
Edits on 21 January, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 January, 2019 10:12 pm
Edits made to:
Infobox (+2/-2 properties)
Infobox
Edits on 17 January, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 January, 2019 9:59 pm
Edits made to:
Article (+22/-22 characters)
Article

Argos Therapeutics is a publicly funded immuno-oncology company based in Durham, North CarolinaDurham, North Carolina. It is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. The technology creates individualized immunotherapies that harness and reprogram dendritic cells to target antigens specific to each person's disease.

Edits on 15 January, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 January, 2019 2:12 pm
Edits made to:
Article (+8/-8 characters)
Article

In December 2018, Argos Therapeutics filed for bankruptcy protection with the U.S. Bankruptcy Court in DelawareDelaware. NASDAQ had also delisted the company's shares earlier in April 2018.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 January, 2019 2:11 pm
Edits made to:
Article (+6/-6 characters)
Article

In December 2018, Argos Therapeutics filed for bankruptcy protection with the U.S. Bankruptcy Court in Delaware. NASDAQNASDAQ had also delisted the company's shares earlier in April 2018.

Edits on 12 January, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 12 January, 2019 12:15 pm
Edits made to:
Infobox (+1 properties)
Description (+10/-11 characters)
Article (+1659 characters)
People (+4 rows) (+8 cells) (+150 characters)
Further reading (+3 rows) (+11 cells) (+676 characters)
Topic thumbnail

Argos Therapeutics

A company decvelopingdeveloping immunotherapy treatments for cancers, infectious and autoimmune diseases

Article

Argos Therapeutics is a publicly funded immuno-oncology company based in Durham, North Carolina. It is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. The technology creates individualized immunotherapies that harness and reprogram dendritic cells to target antigens specific to each person's disease.

Argos' lead product candidate is AGS-003, a combination of Rocapuldencel-T and sunitinib. It is a therapy targeted at treating RCC (renal cell carcinoma) and other cancers. A Phase 3 clinical trial for RCC was initiated in 2013 with Argos also supporting an investor-initiated Phase 2 trials in patients with early stage RCC and non-small cell lunch cancer. It also plans to support other trials for muscle invasive bladder cancer. In April 2018, Argos had announced that it would terminate its Phase 3 trial for AGS-003 on RCC after interim results indicated poor prospects of success.

The company has another product candidate in its pipeline, AGS-004, a treatment for the human immunodeficiency virus (HIV). Investigator-initiated Phase 2 clinical trials are ongoing for the eradication of HIV in adults. Argos also has plans to explore the use of AGS-004 monotherapy to provide long-term control of HIV viral load in otherwise immunologically healthy patient and in pediatric patients infected with HIV, who have otherwise healthy immune systems.

...

In December 2018, Argos Therapeutics filed for bankruptcy protection with the U.S. Bankruptcy Court in Delaware. NASDAQ had also delisted the company's shares earlier in April 2018.

People

Name
Role
Related Golden topics

Charles A. Nicolette

Chief Scientific Officer & VP, Research and Development

Jeffrey D. Abbey

Preside & CEO

Lori R. Harrelson

VP, Finance

Richard D. Katz

CFO

Further reading

Title
Author
Link
Type

Argos Therapeutics bails on late-stage study of Rocapuldencel-T in kidney cancer; shares down 64%

SA Editor Douglas W. House

Web

Durham-based Argos Therapeutics has enough cash to last through end of 2018 | WRAL TechWire

Web

Infobox
Edits on 10 January, 2019
Golden AI
Golden AI edited on 10 January, 2019 10:20 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 December, 2018
Golden AI"Import data"
Golden AI edited on 12 December, 2018 1:09 am
Edits made to:
Infobox (+3 properties)
People (+3 rows) (+6 cells) (+64 characters)
People

Name
Role
Related Golden topics

Alberto Haddad

Investor

Jane Griffin

Employee

Michael Lloyd

Employee

Infobox
Edits on 14 November, 2018
Melanie Manipula"Approved suggestion from source: http://www.argostherapeutics.com"
Melanie Manipula approved a suggestion from Golden's AI on 14 November, 2018 11:30 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 18 September, 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 September, 2018 7:58 pm
Edits made to:
Categories (+1 topics)
Categories
Edits on 19 July, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 July, 2018 8:53 pm
Infobox
Edits on 16 July, 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 July, 2018 11:38 pm
Infobox
Edits on 29 June, 2018
Golden AI"Update infobox"
Golden AI edited on 29 June, 2018 5:50 pm
Infobox
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.